Vaccine

Resilience Approved for $410M Financing from the Department of Defense, in Partnership with the Development Finance Corporation, to Establish Resilient Biomanufacturing Capacity

Retrieved on: 
Friday, March 24, 2023
Biotechnology, Retail, Health, Public Policy, Government, Supply Chain Management, Pharmaceutical, Defense, Stem Cells, Other Defense, Infectious Diseases, Contracts, General Health, Genetics, White House, Federal Government, Vaccine, GMP, Partnership, U.S. Department of Defense Strategy for Operating in Cyberspace, United States Department of Defense, COVID-19, U.S. International Development Finance Corporation, Antibody, Messenger, Protein, DFC, Dicarboxylic acid, National Resilience Institute, Patient, Growth, Ecosystem, Pharmaceutical industry, Resilience

National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).

Key Points: 
  • National Resilience, Inc. (Resilience), a technology-focused biomanufacturing company dedicated to broadening access to complex medicines, today announced that it has signed a finance agreement for $410 million in long-term loan financing from the U.S. Department of Defense (DoD), working with the U.S. International Development Finance Corporation (DFC).
  • The loan financing will support Resilience’s mission to establish significant domestic, end-to-end biomanufacturing capacity and capabilities for biologics (antibodies, proteins, multi-specifics), vaccines, and nucleic acids (including mRNA).
  • Part of the financing will support the implementation of innovative manufacturing platforms and technologies that aim to reduce cost, strengthen the domestic supply chain, and increase the speed of vaccine supply.
  • "The lack of growth and innovation in domestic biomanufacturing was one critical vulnerability that impacted preparedness during the COVID-19 pandemic.

Increasing Investments and Fundings in Cell and Gene Therapy Fuelling the Growth of Cell and Gene Therapy Biomanufacturing, Suggests BIS Research Study

Retrieved on: 
Friday, March 24, 2023
Analytik Jena, GE HealthCare, Gene, Sartorius AG, Merck Group, AAV, DSM-IV codes, Danaher Corporation, Becton, Dickinson and Company headquarters, Incidence, Name, Thermo Fisher Scientific, Investment, General Electric Company, Cancer, Cell, Getinge Group, Growth, Research, Exosome, FDA, Center for Urban and Regional Analysis, PCR, Wuxi, Software, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Fine chemical

FREMONT, Calif., March 24, 2023 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis. 

Key Points: 
  • FREMONT, Calif., March 24, 2023 /PRNewswire/ -- BIS Research, the global leader in providing market intelligence on deep technologies, has released its latest study titled Cell and Gene Therapy Biomanufacturing Market - A Global and Regional Analysis.
  • According to this study, the global cell and gene therapy biomanufacturing market was valued at $12.31 billion in 2022 and is projected to reach $29.76 billion by 2031.
  • Therefore, the impact of the aforementioned factors is expected to drive the global cell and gene therapy biomanufacturing market in the near future."
  • The software solutions segment consists of all the software utilized from manufacturing to logistics in cell and gene therapy biomanufacturing.

HDT Bio Publishes Peer-Reviewed Preclinical Study Demonstrating Robust Immunological Response in Mothers and Newborns Following repRNA/LION™ Vaccination

Retrieved on: 
Friday, March 24, 2023
Vaccine, LION, Duke University, Molecule, Vaccination, HIV-1, Fetus, Infection, Molecular Therapy, Seattle Children's, Publication, Zika virus, Messenger, Risk, Child, Research institute, NIAID, Immunization, Virus, Safety, ZIKV

"The transmission of certain viruses from mother to developing fetus poses a significant risk to newborns," said Steven Reed, Ph.D., Chief Executive Officer of HDT Bio.

Key Points: 
  • "The transmission of certain viruses from mother to developing fetus poses a significant risk to newborns," said Steven Reed, Ph.D., Chief Executive Officer of HDT Bio.
  • Two viruses, HIV-1 and ZIKV, were chosen for the study due to their significant role in causing infections in newborns following mother-to-child transmission.
  • Furthermore, immunization in rabbit kits also led to a robust immunogenic response, regardless of the maternal vaccination status.
  • The publication can be found on the Molecular Therapy website and on the Publications page of the HDT Bio website.

Discovery of Propylene Glycol for its New Powerful Tissue-Regenerative-and-Tissue-Microbicidal Properties in Very Effectively Treating Common Topical Diseases by Scientist, Dr. Win L. Chiou

Retrieved on: 
Friday, March 24, 2023
Bruise, Infection, Travel, University, A. niger, Bleeding, S. aureus, Tooth, Atmosphere, Food, Sunscreen, Nail, Biting, Propylene glycol, Pharmacokinetics, Scar, SPF, Prescription, Mucous membrane, Cutibacterium acnes, Research, PG, Household, Gingivitis, Cosmetics, Multimedia, Fungus, Scalp, Injury, Criticism of the Food and Drug Administration, Publication, Water, Sun, University of Illinois Urbana-Champaign, Irritation, Sun protection, Growth, Inosine pranobex, Bacteria, Burns, Escherichia coli, B cell, FDA, Meat, Virus, Test management, Skin, Wound healing, Vaccine, Pharmaceutical industry, Perfume, Chiou I-jen

Injuries, insect bites and burns are also common; prevention of infection and quick healing of wounds without scarring are of major concern.

Key Points: 
  • Injuries, insect bites and burns are also common; prevention of infection and quick healing of wounds without scarring are of major concern.
  • Currently, there are hundreds or thousands of commercial products available for these uses with many requiring expensive prescriptions.
  • Win L. Chiou " and "Possible dangers and SPF misconceptions of sunscreens for sunbathing investigated by scientist, Dr.
  • Win Chiou, President of Chiou Consulting Inc, can be reached at 630-789-9081 or at [email protected] .

Stuart Peltz, Ph.D., Rare Disease Pioneer, to Retire as Chief Executive Officer of PTC Therapeutics

Retrieved on: 
Friday, March 24, 2023
Yale University, Mitochondrion, PTC Therapeutics, Drug development, University, Gene, The Conference Board, Conference call, PTC, Cancer, Eladocagene exuparvovec, Coronavirus Scientific Advisory Board, European Research Advisory Board, Brain, CMO, RNA, History, CNS, DSM-IV codes, EMA, Bachelor of Arts in Clinical Psychology, Biosensors and Bioelectronics, Shriners Hospitals for Children, ET, Retirement, Oxidative stress, Consultant, Patient, University of Washington Department of Global Health, Stuart, Growth, Mitochondrial disease, Rare, Therapy, Scientific Advisory Group for Emergencies, Conference, Stu, Management, Pharmaceutical industry, Vaccine, Nursing

SOUTH PLAINFIELD, N.J., March 24, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT). Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Under his leadership, PTC has grown from a research organization with expertise in the control of RNA processes to a publicly traded, integrated, global biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for the treatment of neurological and neuromuscular disorders, metabolic disorders, and cancer.

Key Points: 
  • Stuart Peltz, Ph.D., founding Chief Executive Officer (CEO) of PTC Therapeutics announced today that he is stepping down after 25 years.
  • Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development.
  • What Stuart and the team have achieved in 25 years is extraordinary," said Michael Schmertzler, Chairman of the Board of Directors.
  • Matthew Klein, M.D., M.S., F.A.C.S., current Chief Operating Officer, has been named the company's CEO and will join the Board of Directors.

atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights

Retrieved on: 
Friday, March 24, 2023
Consensus, Cognition, Acceleration, GABA, Etifoxine, MCCB, Quantitative electroencephalography, Benzodiazepine, Anxiety, COMP, Brain, COMPASS, Patient, Standard of care, CIAS, Pivotal, Entrepreneurship, TRD, Mental health, Nursing, Vaccine, Pharmaceutical industry, Medical imaging

Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.

Key Points: 
  • Notably, in four clinical studies that assessed cognition, including one in patients with CIAS, the compound consistently demonstrated pro-cognitive effects.
  • More details of the phase 2 clinical development plan will be provided upon initiation of the study.
  • In January 2022, positive results were announced from the phase 1 single and multiple ascending dose study of GRX-917.
  • In the fourth quarter of 2022, the first subject was dosed in a Phase 1 study of VLS-01.

Oncorus Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 24, 2023
Workforce, GMP, Therapy, Hepatocellular carcinoma, Nature Communications, Cancer, Coxsackievirus, RNA, Research, Lung cancer, Public expenditure, Investment, Patient, Melanoma, Immune system, Neoplasm, LNP, FDA, IND, Genome, Renal cell carcinoma, Vaccine, Life insurance, Pharmaceutical industry, Cryptocurrency

We plan to submit an IND with the FDA for ONCR-021 in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus.

Key Points: 
  • We plan to submit an IND with the FDA for ONCR-021 in mid-2023," said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer of Oncorus.
  • Research and development expenses for the quarter ended December 31, 2022 were $15.7 million compared to $14.3 million for the corresponding quarter in 2021.
  • General and administrative expenses for the quarter ended December 31, 2022 were $5.1 million compared to $5.6 million for the corresponding quarter in 2021.
  • Oncorus expects its cash, cash equivalents and investments to fund its capital expenditures and operating expenses into early 2024.

Global Bioengineered Protein Drugs Market to Reach $521.3 Billion by 2027: Increasing Prevalence of Chronic Diseases Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 24, 2023
Health, Pharmaceutical, Vaccine, Therapy, Administration, COVID-19, Ageing, Cancer, Infection, Solubility, Incidence, Protein, Conditional sentence, Dietary supplement, Pharmaceutical industry, Fine chemical

The global bioengineered protein drugs market was estimated to have been worth $327.6 billion in 2021.

Key Points: 
  • The global bioengineered protein drugs market was estimated to have been worth $327.6 billion in 2021.
  • Between 2022 and 2027, the bioengineered protein drugs market is predicted to grow at a compound annual growth rate (CAGR) of 8%, leading to a market value of $521.3 billion in 2027.
  • An aging population with a myriad of chronic diseases, the need for more effective and targeted therapeutics, and continuous innovation in bioengineered protein drugs are driving the bioengineered protein drugs market.
  • Over the past three decades, bioengineered protein drugs have revolutionized the treatment of infectious diseases, cancer, and chronic immunological diseases.

Chemotherapy Induced Diarrhea Epidemiology Forecast 2023 - 2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 24, 2023
Health, Oncology, TKI, CRPC, Capecitabine, Head, Pain, Incidence, Patient, Disease, CT, Therapy, Perception, Toxicity, Research, Classification, Endoscopy, Sepsis, Cervical cancer, Esophageal cancer, Diagnosis, NCI, Total, CTCAE, Neutropenia, Pancreatic cancer, Incident, Hypotension, Dehydration, Fever, Cancer, Lung cancer, Bladder cancer, Blood, Stomach cancer, National Cancer Institute, Chronic pain, Colorectal cancer, Irinotecan, Testicular cancer, Ovarian cancer, Epidemiology, Infection, EU4, Hospital, Quality of life, Stoma, Neck, Physical examination, Endometrial cancer, CID, United Kingdom, Breast cancer, Vaccine, Pharmaceutical industry, Dietary supplement, Dairy, Health insurance, Nursing, Diarrhea

The "Chemotherapy Induced Diarrhea - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chemotherapy Induced Diarrhea - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Chemotherapy-induced Diarrhea (CID) - Epidemiology Forecast - 2032" report delivers an in-depth understanding of the CID, historical and forecasted epidemiology as well as the CID market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
  • Chemotherapy-induced diarrhea (CID), also called chemotherapy-related diarrhea, can be associated with various chemotherapy agents but is most commonly described with fluoropyrimidines (particularly fluorouracil [FU] and capecitabine) and irinotecan.
  • The epidemiology segment also provides Chemotherapy-induced Diarrhea (CID) epidemiology data and findings across the United States, EU4 and the UK, and Japan.

Radiation Dose Management Global Market Report 2023: Increasing Utilization of Diagnostic Imaging Modalities Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, March 24, 2023
Radiology, Health, Component, CT, Internet of things, Cancer, Data collection, PET, Research, History, Google Images, Government, MPE, MRI, Hospital, Magnetic resonance imaging, Patient, Collection, Artificial intelligence, Conditional sentence, R, Safety, Medical imaging, Vaccine, Modality

Radiation dose management assists in facilitating data collection and processing, statistical comparisons, reporting, and management of radiation dose-related information.

Key Points: 
  • Radiation dose management assists in facilitating data collection and processing, statistical comparisons, reporting, and management of radiation dose-related information.
  • Radiation Dose Management Market Trends:
    The increasing utilization of diagnostic imaging modalities across the globe is one of the key factors driving the market growth.
  • Radiation dose management helps in automatically gathering and consolidating the large amounts of dose data generated by imaging modalities.
  • Additionally, the widespread utilization of radiation dose management, which assists in increasing patient safety by tracking radiation exposure history, is propelling the market growth.